m+Medelevator.RU
← Поиск публикаций
Cancer prevention research (Philadelphia, Pa.) · 2019

Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study.

СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Agorastos Theodoros, Chatzistamatiou Kimon, Tsertanidou Athena, Mouchtaropoulou Evangelia, Pasentsis Konstantinos, Kitsou Anastasia, Moysiadis Theodoros, Moschaki Viktoria, Skenderi Alkmini, Katsiki Evangelia, Aggelidou Stamatia, Venizelos Ioannis, Ntoula Maria, Daponte Alexandros, Vanakara Polyxeni, Garas Antonios, Stefos Theodoros, Vrekoussis Thomas, Lymberis Vasilis, Kontomanolis Emmanuel N, Makrigiannakis Antonis, Manidakis George, Deligeoroglou Efthimios, Panoskaltsis Theodoros, Decavalas George O, Michail George, Kalogiannidis Ioannis, Koukoulis George, Zempili Paraskevi, Halatsi Despina, Truva Theoni, Piha Vaia, Agelena Georgia, Chronopoulou Athanasia, Vaitsi Violetta, Chatzaki Ekaterini, Paschopoulos Minas, Adonakis George, Kaufmann Andreas M, Hadzidimitriou Anastasia, Stamatopoulos Kostas

Аннотация

Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25-29 years to 5.1% for women aged 50-60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25-29) to 76.3% (for women 40-49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты